Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw

General Dentistry

Volumn 59, Issue 6, 2011, Pages 410-413

  Wynn, Richard L ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ARTICLE; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); DENTAL PROCEDURE; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; JAW DISEASE; JAW OSTEONECROSIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; CLINICAL TRIALS AS TOPIC; DENTAL CARE FOR CHRONICALLY ILL; DIPHOSPHONATES; DRUG SYNERGISM; HUMANS; JAW DISEASES; OSTEONECROSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856428677     PISSN: 03636771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 2008;19(12):2091-2092.
2. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008;26(24):4037-4038.
3. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009;76(3):209-211. Epub 2009 Feb 12.
4. Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010;122(1):181-188.
5. Miles D, Chan A, Romieu G, Dirix LY , Cortes J, Pivot X, Tomczak P, Taran T, Harbeck N, Steger GG. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metatstatic breast cancer (mBC): AVADO. J Clin Oncol 2008;26(15S): (Abstract LBA1011).
6. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metatstatic breast cancer. J Clin Oncol 2011;29(10):1252-1260.
7. Hoff AO , Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23(6):826-836. (Pubitemid 351768801)
8. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer patients after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005;23(34):8580-8587. (Pubitemid 46211499)
9. Van Poznak C Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Res Treat 2010;122(1):189-191.
10. Francini F, Pascucci A, Francini E, Miano ST, Bargagli G, Ruggiero G, Petriolli R. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab. J Am Dent Assoc 2011;142(5):506-513.
11. Drug information handbook for dentistry, ed. 16, 2010-2011. Wynn RL, Meiller TF, Crossley HC. Hudson, OH: LexiComp, Inc.;2011:232.